REPORT: State of Oligo, Peptide, mRNA and CRISPR Therapeutics 2019
In June this year, we conducted a survey of oligonucleotide, peptide, CRISPR and mRNA therapeutics professionals from around the world.
Based on 124 responses, this report gives an overview of how insiders really view the state of the industry, revealing unique insights into potential opportunities and challenges around drug development, manufacture, delivery, technologies, regulations and collaborations.
